
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
On a global scale, Frontage Central Lab Business is assisting clients with their drug development needs across all clinical phases. In this podcast, the Frontage Central lab team will discuss some of the best practices to keep in mind when choosing a lab partner for PK/PD and routine/specialty central lab support.






